These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33430855)

  • 1. Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling.
    Jiang H; Tang JY; Xue D; Chen YM; Wu TC; Zhuang QF; He XZ
    Cancer Cell Int; 2021 Jan; 21(1):41. PubMed ID: 33430855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of assembly factor for spindle microtubules triggers progression of renal cell carcinoma via Wnt3a pathway.
    Cao Z; Li Y; Xu C; Zhang Z; Wang Z; Ma Z; Xu P; Sun X; He X; Zhang J; Jiang H; Li G
    J Cancer; 2023; 14(17):3248-3257. PubMed ID: 37928425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma.
    Cui Y; Miao C; Hou C; Wang Z; Liu B
    Front Oncol; 2020; 10():1436. PubMed ID: 32974161
    [No Abstract]   [Full Text] [Related]  

  • 4. Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer.
    Ren H; Chen Z; Yang L; Xiong W; Yang H; Xu K; Zhai E; Ding L; He Y; Song X
    Cancer Manag Res; 2019; 11():4917-4930. PubMed ID: 31213910
    [No Abstract]   [Full Text] [Related]  

  • 5. APOC1 promotes the progression of osteosarcoma by binding to MTCH2.
    Li R; He H; He X
    Exp Ther Med; 2023 Apr; 25(4):163. PubMed ID: 36911382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Cervical Cancer.
    Shi X; Wang J; Dai S; Qin L; Zhou J; Chen Y
    Onco Targets Ther; 2020; 13():12881-12891. PubMed ID: 33364782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis.
    Ren L; Yi J; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang X; Wang J
    Pharmacol Res; 2022 Sep; 183():106376. PubMed ID: 35914680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Apoc1 reverses resistance of sorafenib by promoting ferroptosis in esophageal cancers.
    Hu J; Hu H; Liu Q; Feng B; Lu Y; Chen K
    Gene; 2024 Jan; 892():147874. PubMed ID: 37804922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
    Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
    Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial.
    Ko HL; Wang YS; Fong WL; Chi MS; Chi KH; Kao SJ
    Thorac Cancer; 2014 Nov; 5(6):500-8. PubMed ID: 26767044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt3a expression is associated with epithelial-mesenchymal transition and promotes colon cancer progression.
    Qi L; Sun B; Liu Z; Cheng R; Li Y; Zhao X
    J Exp Clin Cancer Res; 2014 Dec; 33(1):107. PubMed ID: 25499541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing miR-454 suppresses cell proliferation, migration and invasion via directly targeting MECP2 in renal cell carcinoma.
    Liu H; Liu QL; Zhai TS; Lu J; Dong YZ; Xu YF
    Am J Transl Res; 2020; 12(8):4277-4289. PubMed ID: 32913504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Tescalcin inhibits growth and metastasis in renal cell carcinoma via downregulating NHE1 and NF-kB signaling.
    Luo AJ; Tan J; He LY; Jiang XZ; Jiang ZQ; Zeng Q; Yao K; Xue J
    Exp Mol Pathol; 2019 Apr; 107():110-117. PubMed ID: 30594602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
    Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro.
    Su WP; Sun LN; Yang SL; Zhao H; Zeng TY; Wu WZ; Wang D
    J Biochem Mol Toxicol; 2018 May; 32(7):e22158. PubMed ID: 29719090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer.
    Yi J; Ren L; Wu J; Li W; Zheng X; Du G; Wang J
    Ann Transl Med; 2019 Aug; 7(16):380. PubMed ID: 31555694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated expression of KIF18A enhances cell proliferation and predicts poor survival in human clear cell renal carcinoma.
    Chen QI; Cao B; Nan N; Wang YU; Zhai XU; Li Y; Chong T
    Exp Ther Med; 2016 Jul; 12(1):377-383. PubMed ID: 27347065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
    Hao P; Kang B; Li Y; Hao W; Ma F
    Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.